Indication: Breast Cancer
A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced
Advanced or Metastatic HR+ / HER2-
Sub-indication: ER+ breast cancer- Second line or third line (as long as no more than one previous chemotherapy), patient had to have been treated previously after they were metastatic.
Line of Therapy: 2nd or 3rd Line
Principal Investigator: Laila Agrawal, M.D.Norton Cancer Institute
Email for more information: Breast-NCIResearch@nortonhealthcare.org